MEDIPREN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MEDIPREN (MEDIPREN).
Non-selective COX-1 and COX-2 inhibition, reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
| Metabolism | Primarily hepatic via CYP2C9 and CYP2C8; also undergoes phase II conjugation (glucuronidation). |
| Excretion | Renal: 90-95% as sulfate and glucuronide conjugates; <5% unchanged. Biliary/fecal: <5%. |
| Half-life | Terminal elimination half-life: 2-3 hours. Prolonged in hepatic impairment or overdose. |
| Protein binding | 10-25% bound to albumin. |
| Volume of Distribution | Vd: 0.9-1.0 L/kg; indicates distribution throughout total body water. |
| Bioavailability | Oral: 85-90%; Rectal: 80-90%; IV: 100%. |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes; Rectal: 30-60 minutes. |
| Duration of Action | 4-6 hours; extended by hepatic disease or overdose. |
200-400 mg orally every 4-6 hours as needed, not to exceed 1200 mg per day.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-59 mL/min: not to exceed 600 mg/day. eGFR <30 mL/min: not to exceed 400 mg/day. Dialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: not to exceed 600 mg/day. Child-Pugh C: contraindicated. |
| Pediatric use | 5-10 mg/kg orally every 6-8 hours, not to exceed 40 mg/kg/day or 1200 mg/day. |
| Geriatric use | Initial dose 200 mg every 6-8 hours; maximum 600 mg/day due to increased risk of gastrointestinal and renal adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MEDIPREN (MEDIPREN).
| Breastfeeding | Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01). Considered compatible with breastfeeding; use lowest effective dose for shortest duration. |
| Teratogenic Risk | Medipren (ibuprofen) is an NSAID. First trimester: limited data, but increased risk of miscarriage; avoid if possible. Second trimester: considered relatively safe at lowest effective dose. Third trimester: contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
■ FDA Black Box Warning
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk may be higher in patients with cardiovascular disease or risk factors. NSAIDs are also associated with an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
| Serious Effects |
Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after taking NSAIDs, perioperative pain in CABG surgery, active peptic ulcer or GI bleeding, severe heart failure, and third trimester of pregnancy.
| Precautions | Cardiovascular risk, gastrointestinal ulceration/bleeding, renal impairment, hypertension, fluid retention, asthma exacerbation, hepatic impairment, anemia, and skin reactions (including Stevens-Johnson syndrome). |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal renal function, blood pressure, and signs of bleeding. In third trimester, monitor amniotic fluid volume (oligohydramnios) and fetal ductus arteriosus via ultrasound. |
| Fertility Effects | Ibuprofen may reversibly impair female fertility by inhibiting prostaglandin synthesis, affecting ovulation. Effect resolves upon discontinuation. No known male fertility impairment. |